BridgeBio Pharma SG&A Expenses 2018-2024 | BBIO

BridgeBio Pharma sg&a expenses from 2018 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
BridgeBio Pharma Annual SG&A Expenses
(Millions of US $)
2023 $151
2022 $143
2021 $192
2020 $146
2019 $94
2018 $44
2017 $13
BridgeBio Pharma Quarterly SG&A Expenses
(Millions of US $)
2024-06-30 $60
2024-03-31 $66
2023-12-31 $48
2023-09-30 $36
2023-06-30 $36
2023-03-31 $31
2022-12-31 $32
2022-09-30 $31
2022-06-30 $36
2022-03-31 $44
2021-12-31 $55
2021-09-30 $46
2021-06-30 $46
2021-03-31 $45
2020-12-31 $37
2020-09-30 $36
2020-06-30 $38
2020-03-31 $34
2019-12-31 $35
2019-09-30 $23
2019-06-30 $17
2019-03-31 $19
2018-12-31
2018-09-30 $10
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.629B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.384B 6.36
Dr Reddy's Laboratories (RDY) India $12.329B 23.59
Bausch Health Cos (BHC) Canada $3.358B 2.43
Amphastar Pharmaceuticals (AMPH) United States $2.294B 13.79
Supernus Pharmaceuticals (SUPN) United States $2.089B 28.44
Taysha Gene Therapies (TSHA) United States $0.490B 79.67
Personalis (PSNL) United States $0.278B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00